Malte Peters
President, CEO & DirectorDr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until March 2024 and served as Independent Director since January 01, 2023 until 2024 and serves as its President since July 22, 2024. He had been Chief Research and Development Officer at MorphoSys AG from March 01, 2020 to October 1, 2022 and served as its Member of Management Board until October 1, 2022 but remain as its Executive Officer to ensure smooth transition. He served as Chief Development Officer at MorphoSys AG since March 01, 2017 until March 01, 2020. Dr. Peters joined MorphoSys from Sandoz, where he served as Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to Sandoz, he served as Vice President of Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters served as an Independent Director of Tango Therapeutics, Inc. since September 2018 until January 08, 2026 and serves as its Chief Executive Offcier, President & Director since January 08, 2026. From 2004 to 2015, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Before that, Dr. Peters served in positions as Medical Director at Micromet AG and as Head of Translational Research and Pharmacogenomics at Merck KGaA. Dr. Peters built his career in early and late-stage clinical development over the last many years. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany. After scientific work at different universities, he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany. He also served as a research scientist in infectious disease. Dr. Peters received his MD degree from the Freie Universit?t Berlin, Germany and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany.
Positions
- Company NameTango Therapeutics, Inc.Stock CodeTNGXPositionPresident, CEO & DirectorColleagues
- RWRobert William AzelbyIndependent Chairman of the Board
- BLBarbara L. WeberExecutive Officer
- ASAdam S. CrystalPresident of Research & Development
- AAAlan AshworthFounder & Member of Scientific Advisory Board
- WGWilliam G. KaelinFounder & Member of Scientific Advisory Board
- ARAntoni RibasFounder & Member of Scientific Advisory Board
